SLC5A2 and heart failure: Similarly, in another recent meta-analysis concerning patients with heart failure, SGLT2 inhibitors exerted a borderline reduction in SBP [−1.68 (95% CI: −2.7 to −0.66) mmHg], without significant alterations in DBP, while the heart rate of patients remained unchanged.